RESUMEN
OBJECTIVES: To evaluate asthma characteristics and treatment patterns, including short-acting ß2-agonist (SABA) prescriptions, in primary and specialist care in the Singapore cohort of the SABA use IN Asthma (SABINA III) study. DESIGN: Cross-sectional, observational study. SETTING: Multicentre study conducted at five sites across Singapore. METHODS: In patients with asthma (aged ≥12 years), data on demographics, disease characteristics and asthma treatment prescriptions were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by 2017 Global Initiative for Asthma recommendations) and practice type (primary/specialist care). RESULTS: Of the 205 patients analysed (mean (SD) age, 53.6 (16.8) years; female, 62%), 55.9% were enrolled by specialists and 44.1% by primary care physicians. Most study patients (80.5%) had moderate-to-severe asthma (86.0% in specialist care and 74.4% in primary care). In the 12 months before study enrolment, 18.0% of patients experienced ≥1 severe exacerbation. Asthma was well or partly controlled in 78.0% of patients. Overall, 17.1% of all patients were overprescribed SABA (≥3 SABA canisters/year) in the preceding 12 months, and overprescription was greater in specialist versus primary care (26.3% vs 5.6%). Only 2.9% of patients were prescribed SABA monotherapy, while 41.0% received SABA in addition to maintenance therapy. Among the latter, 40.5% were overprescribed SABA. Overall, a higher percentage of patients prescribed ≥3 SABA canisters (vs 0-2 SABA canisters) were assessed as having uncontrolled asthma during the study visit (42.9% vs 17.6%). Maintenance therapy in the form of inhaled corticosteroids (ICS) or ICS/long-acting ß2 agonist fixed-dose combinations were prescribed to 14.1% and 84.9% of patients, respectively, in the 12 months before enrolment. CONCLUSIONS: In this Singapore cohort, ~17% of all patients and more than 40% of patients prescribed SABA in addition to maintenance therapy were overprescribed SABA. These findings emphasise the need to align clinical practices with the latest evidence-based treatment recommendations. TRIAL REGISTRATION: NCT03857178.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2 , Antiasmáticos , Asma , Pautas de la Práctica en Medicina , Humanos , Asma/tratamiento farmacológico , Femenino , Estudios Transversales , Singapur , Masculino , Persona de Mediana Edad , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Adulto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Anciano , Antiasmáticos/uso terapéutico , Índice de Severidad de la Enfermedad , Atención Primaria de Salud/estadística & datos numéricosRESUMEN
The year 2009 marks the 100th anniversary of the first Nobel Prize to be awarded to a surgeon, Emil Theodor Kocher. Kocher was a surgical pioneer and in 1909 was awarded the Nobel Prize in Physiology or Medicine for his contributions to the understanding and treatment of the thyroid gland. What is lesser known are his contributions to neurosurgery. He published articles on traumatic epilepsy, brain damage and trepanation. Together with Harvey Cushing, they pioneered and expanded on research of the physiology of intracranial pressure, which led to the advent of the Cushing-Kocher theory.